| abstract |
A dibenzofuran-4,6-dicarboxylic acid core structure having an aromatic substituent attached at the C1-position using three different types of linkages is disclosed in the present invention and is compared to lead compound 1. Thus, it is shown to be an abnormal amyloidogenesis inhibitor that exhibits increased affinity and markedly increased binding selectivity for TTR over all other plasma proteins. The present invention further shows that these compounds function by imposing dynamic stabilization on the TTR tetramer. |